36 Kr starter | Seizing the IVD track of the ophthalmology market, "Zhide Test" was led by Northern Lights with a 20 million Pre-A round of financing

36Kr learned that Beijing Zhide Medical Laboratory Co., Ltd., a professional organization engaged in accurate ophthalmic examination, recently announced the completion of a Pre-A round of financing of 20 million yuan. It is reported that this round of financing is led by Northern Lights Venture Capital, followed by Yuanyi Capital and Dr. Tan Zhi.

With the deepening of the aging trend and the change of people's eye habits, the demand for ophthalmology has gradually increased. According to the data of the Third China Eye Health Conference, the number of patients with eye diseases in China exceeds 150 million, which has far exceeded that of European and American countries. The incidence of ophthalmic diseases such as uveitis, retinal diseases, and allergic conjunctivitis is increasing.

Ophthalmology has become a huge market in rapid growth, the global market size is about 40 billion US dollars, the domestic market size is 3.2 billion US dollars, but there are not many excellent targets in the track, and innovative companies in the domestic ophthalmology field are even more scarce.

Zhide Inspection is the representative enterprise of ophthalmology precision examination, with a leading domestic all-round third-party detection platform for difficult eye diseases, and covers multiple professional ophthalmic precision detection fields such as Uveitis LDT and IVD, retinal choroidal diseases such as FUNDID, allergic conjunctivitis, dry eye disease and other ophthalmic surface diseases POCT, providing clinicians and patients with one-stop service of ophthalmic etiology detection, medical advice, medical consultation and scientific research cooperation.

Image courtesy of Essence Securities

Compared with competitors, the core advantage of Zhide Testing lies in the leading eye disease detection foundation and the accumulation of massive clinical and testing data. "The core barrier of Zhide inspection comes from the exclusive trace detection technology of intraocular fluid, and its business has covered 22 provinces, cooperated with more than 300 hospitals in China, and has detected more than 50,000 cases of various eye disease specimens, and has perfect self-built channels and cooperative sales channels in China." The Zhide test is indicated to 36 Kr.

Ophthalmic IVD and POCT are relatively blank in the market, and Zhide Inspection can also quickly develop related applications by virtue of the accumulation of data and technology, which is because the core technology between products is common.

Founded in June 2016, Zhide Inspection has more than 1,000 square meters of testing, R&D and production bases in Beijing, of which the laboratory area is 880 square meters, and is built in strict accordance with ISO15189 and national biosecurity level II standards.

After the completion of this round of financing, Zhide Inspection will accelerate the research and development of IVD product systems for a variety of ophthalmic diseases, the recruitment of scientific researchers and the construction of production bases, while accelerating the market layout to provide faster and more accurate detection solutions for patients with ophthalmic diseases around the world.